The World Market for Cardiovascular Diagnostics
This report provides the reader with an overview of the global cardiac diagnostics industry and the trends driving growth. Segments within the cardiac diagnostic market include:
Economic conditions in several markets within the global cardiac diagnostics market remained challenging in 2012. Demand for cardiovascular diagnostics slowed during the historical period due to a weakened global economy, cost cutting measures and healthcare reform issues. However, demographics worldwide and an aging world society remain primary factors in growth. By 2020, 16 percent of the US population will be over the age of 65, up from 13% in 2010. People are also living longer, needing more health care, further fueling the market. In 1980, the US life expectancy at birth was 74 years, today the average American lives to be 78 years old.
The global cardiac diagnostic industry is a diverse and highly competitive market. It is anticipated that provider demand for cardiac diagnostic products and services will continue to rise providing opportunities for both existing market participants and emerging market participants. Manufacturers should look for ways to distinguish themselves in the marketplace by keeping abreast of key market drivers, restraints, and trends that are affecting the market and the economy as a whole. More than ever before, manufacturers are facing survival challenges in today’s marketplace while the need for innovative and safe products continues to grow.
Companies profiled in this report include:
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with more than 21 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.
- Electrocardiography including ECG testing, stress testing, Holter monitoring, event monitoring and implantable loop.
- Cardiac imaging including non-invasive X-Ray, MRI, CT, ultrasound, and nuclear cardiography; and invasive /cardiac catheterization/angiography, intravascular ultrasound, optical coherence technology and electrophysiology.
- Cardiac point-of-care including cholesterol testing and coagulation testing
- Cardiac markers
- Cardiac contrast agents and radiopharmaceuticals
Economic conditions in several markets within the global cardiac diagnostics market remained challenging in 2012. Demand for cardiovascular diagnostics slowed during the historical period due to a weakened global economy, cost cutting measures and healthcare reform issues. However, demographics worldwide and an aging world society remain primary factors in growth. By 2020, 16 percent of the US population will be over the age of 65, up from 13% in 2010. People are also living longer, needing more health care, further fueling the market. In 1980, the US life expectancy at birth was 74 years, today the average American lives to be 78 years old.
The global cardiac diagnostic industry is a diverse and highly competitive market. It is anticipated that provider demand for cardiac diagnostic products and services will continue to rise providing opportunities for both existing market participants and emerging market participants. Manufacturers should look for ways to distinguish themselves in the marketplace by keeping abreast of key market drivers, restraints, and trends that are affecting the market and the economy as a whole. More than ever before, manufacturers are facing survival challenges in today’s marketplace while the need for innovative and safe products continues to grow.
Companies profiled in this report include:
- Abbott Diagnostics
- Acusphere
- Alere
- Analogic Corp
- Bayer Healthcare
- Bracco SpA
- Cardinal Health
- CardioDX
- C.R. Bard
- Danaher Corporation
- dpiX
- FluoroPharma Medical
- GE Healthcare
- Johnson & Johnson
- King Pharmaceuticals
- Lantheus Medical Imaging
- LipScience
- Medison America
- Molecular Insight Pharmaceuticals
- Nanosphere
- PerkinElmer
- Philips Healthcare
- Roche Diagnostics
- Shimadzu Corp
- Siemens Medical Solutions
- St Jude Medical
- Terumo Medical
- TomTec Imaging Systems
- Trixell
- Vascular Solutions
- Vermillion
- Volcano
The information for this report was gathered using both primary and secondary research including comprehensive research of secondary sources such as company literature, databases, investment reports, and medical and business journals. Telephone interviews and email correspondence were the primary method of gathering information. For the purpose of this study, Kalorama Information conducted interviews with more than 21 key industry officials, consultants, health care providers, and government personnel. These sources were the primary basis in gathering information specifically relating to revenue and market share data presented in this report. Additional interviews were completed with relevant company representatives including marketing directors, division managers, and product representatives.
CHAPTER ONE: EXECUTIVE SUMMARY
Industry at a Glance
Scope and Methodology
Size and Growth of the Market
Key Issues and Trends Affecting the Market
Leading Market Participants
CHAPTER TWO: INDUSTRY OVERVIEW
Introduction
Cardiovascular Anatomy
Heart
Circulatory System
Cardiac Cycle
Coronary Circulation
Cardiac Myocytes
Molecular Contraction
Diseases of the Heart
Ischemic Heart Disease
Etiology
Pathophysiology
Atherosclerosis
Angina Pectoris
Acute Ischemia and Myocardial Infarction Chronic
Chronic Ischemic Cardiomyopathy
Sudden Cardiac Death
Diagnostic Tests
Valvular and Endocardial Diseases
Mitral Valve Disorders
Aortic Valve Disorders
Rheumatic Heart Disease
Endocarditis
Diagnostic Tests
Pericardial Diseases
Pericardial Effusion
Pericarditis
Myocardial Diseases
Myocarditis
Cardiomyopathy
Diagnostic Tests
Congenital Heart Diseases
Atrial Septal Defect
Ventral Septal Defect
Pulmonary Stenosis
Aortic Stenosis
Coarctation of the Aorta
Patent Ductus Arteriosus
Truncus Arteriosus
Transposition of the Great Arteries
Tricuspid Atresia
Congestive Heart Failure
Etiology
Diagnostic Tests
Cardiac Dysrhythmias
Diagnostic Tests Hypertension
Risk Factors
Effects of High Blood Pressure
CHAPTER THREE: ELECTROCARDIOGRAPHY
Introduction
Market Size and Growth
CHAPTER FOUR: CARDIAC DIAGNOSTIC IMAGING
Non-Invasive Cardiac Imaging
X-Ray
MRI
Ultrasound
Computed Tomography
Electron Beam Computed Tomography
Dual Source Computed Tomography
Nuclear Cardiography
Invasive Transcatheter Cardiac Imaging
Cardiac Catheterization/Angiography Products
Intravascular Ultrasound
Optical Coherence Tomography
Electrophysiology
Market Size and Growth
Noninvasive Imaging
Invasive Transcatheter Imaging
CHAPTER FIVE: CARDIAC DIAGNOSTIC POINT OF CARE TESTING
Coagulation Testing
Cholesterol Testing
Total Cardiac Diagnostic Point-of- Care Market Size and Growth
CHAPTER SIX: CARDIAC MARKERS
Total Cardiac Markers Market Size and Growth
CHAPTER SEVEN: CARDIAC DIAGNOSTIC CONTRAST AGENTS AND RADIOPHARMACEUTICALS
Contrast Agents
Radiopharmaceuticals
Total Cardiac Diagnostic Contrast Agents and Radiopharmaceuticals Market Size and Growth
CHAPTER EIGHT: MARKET PARTICIPANTS
Summary
Abbott Diagnostics
Company Overview
Products
Acusphere
Alere, Inc
Company Overview
Products
Locations
Analogic Corp
Bayer Healthcare
Company Overview
Products
Bracco SpA
Cardinal Health
CardioDX, Inc
Company Overview
Products
C.R. Bard
Danaher Corporation
Company Overview
Products
dpiX, LLC
FluoroPharma Medical
GE Healthcare
Company Overview
Products and Services
Locations
Hitachi Medical Systems America, Inc.
Johnson & Johnson
Company Overview
Products
King Pharmaceuticals
Lantheus Medical Imaging
LipoScience, Inc
Company Overview
Products
Medison America, Inc.
Molecular Insight Pharmaceuticals, Inc.
Nanosphere, Inc.
Company Overview
Products
PerkinElmer
Philips Healthcare
Company Overview
Products and Services
Locations
Roche Diagnostics US (Div of Roche)
Company Overview
Products
Locations
Shimadzu Corp
Siemens Medical Solutions
Company Overview
Products and Services
St. Jude Medical
Company Overview
Products
Terumo Medical Corporation
TomTec Imaging Systems GmbH
Toshiba America Medical Systems, Inc
Company Overview
Products and Services
Trixell
Vascular Solutions
Vermillion, Inc
Company Overview
Products
Volcano Corp
Company Overview
Products
Locations
CHAPTER NINE: MARKET TRENDS AND SUMMARY
Market Overview
Market Revenues by Product Type
Global Cardiac Diagnostic Market Analysis by Region
United States
Europe
Japan
Rest of World
Competitive Analysis
CHAPTER TEN: INDUSTRY DEVELOPMENTS AND TECHNOLOGIES
Demographics
Cardiovascular Disease Worldwide
European Cardiovascular Disease Statistics
US-Specific Population Demographics
Population Over Age 65 Life Expectancy
Increasing Incidence of Disease
New Cardiac CT Device
CT Spots Seeds of Heart Disease in Healthy Patients
Contrast Agent Toxicity
Contrast Agents Generic Competition
MRI Catheter Guidance
Healthcare Reform
CHAPTER ELEVEN: CONCLUSIONS
LIST OF COMPANIES
Industry at a Glance
Scope and Methodology
Size and Growth of the Market
Key Issues and Trends Affecting the Market
Leading Market Participants
CHAPTER TWO: INDUSTRY OVERVIEW
Introduction
Cardiovascular Anatomy
Heart
Circulatory System
Cardiac Cycle
Coronary Circulation
Cardiac Myocytes
Molecular Contraction
Diseases of the Heart
Ischemic Heart Disease
Etiology
Pathophysiology
Atherosclerosis
Angina Pectoris
Acute Ischemia and Myocardial Infarction Chronic
Chronic Ischemic Cardiomyopathy
Sudden Cardiac Death
Diagnostic Tests
Valvular and Endocardial Diseases
Mitral Valve Disorders
Aortic Valve Disorders
Rheumatic Heart Disease
Endocarditis
Diagnostic Tests
Pericardial Diseases
Pericardial Effusion
Pericarditis
Myocardial Diseases
Myocarditis
Cardiomyopathy
Diagnostic Tests
Congenital Heart Diseases
Atrial Septal Defect
Ventral Septal Defect
Pulmonary Stenosis
Aortic Stenosis
Coarctation of the Aorta
Patent Ductus Arteriosus
Truncus Arteriosus
Transposition of the Great Arteries
Tricuspid Atresia
Congestive Heart Failure
Etiology
Diagnostic Tests
Cardiac Dysrhythmias
Diagnostic Tests Hypertension
Risk Factors
Effects of High Blood Pressure
CHAPTER THREE: ELECTROCARDIOGRAPHY
Introduction
Market Size and Growth
CHAPTER FOUR: CARDIAC DIAGNOSTIC IMAGING
Non-Invasive Cardiac Imaging
X-Ray
MRI
Ultrasound
Computed Tomography
Electron Beam Computed Tomography
Dual Source Computed Tomography
Nuclear Cardiography
Invasive Transcatheter Cardiac Imaging
Cardiac Catheterization/Angiography Products
Intravascular Ultrasound
Optical Coherence Tomography
Electrophysiology
Market Size and Growth
Noninvasive Imaging
Invasive Transcatheter Imaging
CHAPTER FIVE: CARDIAC DIAGNOSTIC POINT OF CARE TESTING
Coagulation Testing
Cholesterol Testing
Total Cardiac Diagnostic Point-of- Care Market Size and Growth
CHAPTER SIX: CARDIAC MARKERS
Total Cardiac Markers Market Size and Growth
CHAPTER SEVEN: CARDIAC DIAGNOSTIC CONTRAST AGENTS AND RADIOPHARMACEUTICALS
Contrast Agents
Radiopharmaceuticals
Total Cardiac Diagnostic Contrast Agents and Radiopharmaceuticals Market Size and Growth
CHAPTER EIGHT: MARKET PARTICIPANTS
Summary
Abbott Diagnostics
Company Overview
Products
Acusphere
Alere, Inc
Company Overview
Products
Locations
Analogic Corp
Bayer Healthcare
Company Overview
Products
Bracco SpA
Cardinal Health
CardioDX, Inc
Company Overview
Products
C.R. Bard
Danaher Corporation
Company Overview
Products
dpiX, LLC
FluoroPharma Medical
GE Healthcare
Company Overview
Products and Services
Locations
Hitachi Medical Systems America, Inc.
Johnson & Johnson
Company Overview
Products
King Pharmaceuticals
Lantheus Medical Imaging
LipoScience, Inc
Company Overview
Products
Medison America, Inc.
Molecular Insight Pharmaceuticals, Inc.
Nanosphere, Inc.
Company Overview
Products
PerkinElmer
Philips Healthcare
Company Overview
Products and Services
Locations
Roche Diagnostics US (Div of Roche)
Company Overview
Products
Locations
Shimadzu Corp
Siemens Medical Solutions
Company Overview
Products and Services
St. Jude Medical
Company Overview
Products
Terumo Medical Corporation
TomTec Imaging Systems GmbH
Toshiba America Medical Systems, Inc
Company Overview
Products and Services
Trixell
Vascular Solutions
Vermillion, Inc
Company Overview
Products
Volcano Corp
Company Overview
Products
Locations
CHAPTER NINE: MARKET TRENDS AND SUMMARY
Market Overview
Market Revenues by Product Type
Global Cardiac Diagnostic Market Analysis by Region
United States
Europe
Japan
Rest of World
Competitive Analysis
CHAPTER TEN: INDUSTRY DEVELOPMENTS AND TECHNOLOGIES
Demographics
Cardiovascular Disease Worldwide
European Cardiovascular Disease Statistics
US-Specific Population Demographics
Population Over Age 65 Life Expectancy
Increasing Incidence of Disease
New Cardiac CT Device
CT Spots Seeds of Heart Disease in Healthy Patients
Contrast Agent Toxicity
Contrast Agents Generic Competition
MRI Catheter Guidance
Healthcare Reform
CHAPTER ELEVEN: CONCLUSIONS
LIST OF COMPANIES
LIST OF EXHIBITS
CHAPTER ONE:EXECUTIVE SUMMARY
Summary Table
Global Cardiac Diagnostics Market Analysis, 2010-2017
Summary Figure
Global Cardiac Diagnostics Market Analysis: 2010-2017
CHAPTER THREE: ELECTROCARDIOGRAPHY
Table 3-1 Total Electrocardiography Testing Market Analysis, 2010-2017
Figure 3-1 Total Electrocardiography Testing Market Analysis, 2010-2017
CHAPTER FOUR: IMAGING MARKET
Table 4-1 Non-Invasive Cardiac Imaging Market Analysis, 2010-2017
Table 4-2 Invasive Transcatheter Cardiac Imaging Market Analysis, 2010-2017
Table 4-3 Total Cardiac Diagnostic Imaging Market Analysis, 2010-2017
Figure 4-1 Total Cardiac Diagnostic Imaging Market Analysis, 2010-2017
CHAPTER FIVE: CARDIAC POINT OF CARE TESTING
Table 5-1 Cardiac Coagulation Testing Market Analysis, 2010-2017
Table 5-2 Cardiac Cholesterol Testing Market Analysis, 2010-2017
Table 5-3 Total Cardiac Diagnostic POC Testing Market Analysis, 2010-2017
Figure 5-1 Total Cardiac Diagnostic POC Testing Market Analysis, 2010-2017
CHAPTER SIX: CARDIAC MARKERS
Table 6-1 Total Cardiac Markers Market Analysis, 2010-2017
Figure 6-1 Total Cardiac Markers Market Analysis, 2010-2017
CHAPTER SEVEN: CARDIAC CONTRAST AGENTS
Table 7-1 Total Cardiac Diagnostic Contrast Agent and Radiopharmaceuticals Market Analysis,2010-2017
Figure 7-1 Total Cardiac Diagnostic Contrast Agent and Radiopharmaceuticals Market Analysis,2010-2017
CHAPTER NINE: MARKET TRENDS AND SUMMARY
Table 9-1 Global Cardiac Diagnostics Market Analysis, 2010-2017
Figure 9-1 Global Cardiac Diagnostics Market Analysis: 2010-2017
Table 9-2 Global Cardiac Diagnostics by Type Revenues and Percent of Market 2012 (in millions of dollars at the manufacturers’ level)
Figure 9-2 Global Cardiac Diagnostics by Type Revenues and Percent of Market 2012
Table 9.3 Global Cardiac Diagnostic by Type Revenues and Percent of Market 2017 (in millions of dollars at the manufacturers’ level)
Figure 9-3 Global Cardiac Diagnostics by Type Revenues and Percent of Market 2016
Table 9-4 Global Cardiac Diagnostics Market Revenues by Region 2012 ($millions)
Figure 9-4 Global Cardiac Diagnostics Market Revenues by Region 2012 ($millions)
Figure 9-5 Global Cardiac Diagnostics by Region Percent 2012 (%)
Table 9-5 Global Cardiac Diagnostics Market Revenues by Region 2017 ($millions)
Figure 9-6 Global Cardiac Diagnostics Market Revenues by Region 2017 ($millions)
Figure 9-7 Global Cardiac Diagnostics by Region Percent 2017 (%)
Table 9-6 Estimated Global Cardiac Diagnostics Manufacturer Market Share 2012
Figure 9-8 Estimated Global Cardiac Diagnostics Revenues and Market Share 2012
CHAPTER TEN: INDUSTRY DEVELOPMENTS AND TECHNOLOGIES ..165
Table 10-1 Total Global Population by Selected Geographical Region, 2000 - 2050
Table 10-2 Cardiovascular Deaths by World Region 2008
Table 10-3 The U.S. Population, 1980-2020
Figure 10-1 The US Population, 1980-2020 (in millions)
Table 10-4 Percent U.S. Population Over Age 65 by Year
Figure 10-2 Estimated Population by Age Group, 2000 and 2050
Table 10-5 Average U.S. Life Expectancy in Years 1980, 2004, 2006, 2010, 2011 (years)
Figure 10-3 Average U.S. Life Expectancy in Years 1980, 2004, 2006, 2010, 2011
APPENDIX
CHAPTER ONE:EXECUTIVE SUMMARY
Summary Table
Global Cardiac Diagnostics Market Analysis, 2010-2017
Summary Figure
Global Cardiac Diagnostics Market Analysis: 2010-2017
CHAPTER THREE: ELECTROCARDIOGRAPHY
Table 3-1 Total Electrocardiography Testing Market Analysis, 2010-2017
Figure 3-1 Total Electrocardiography Testing Market Analysis, 2010-2017
CHAPTER FOUR: IMAGING MARKET
Table 4-1 Non-Invasive Cardiac Imaging Market Analysis, 2010-2017
Table 4-2 Invasive Transcatheter Cardiac Imaging Market Analysis, 2010-2017
Table 4-3 Total Cardiac Diagnostic Imaging Market Analysis, 2010-2017
Figure 4-1 Total Cardiac Diagnostic Imaging Market Analysis, 2010-2017
CHAPTER FIVE: CARDIAC POINT OF CARE TESTING
Table 5-1 Cardiac Coagulation Testing Market Analysis, 2010-2017
Table 5-2 Cardiac Cholesterol Testing Market Analysis, 2010-2017
Table 5-3 Total Cardiac Diagnostic POC Testing Market Analysis, 2010-2017
Figure 5-1 Total Cardiac Diagnostic POC Testing Market Analysis, 2010-2017
CHAPTER SIX: CARDIAC MARKERS
Table 6-1 Total Cardiac Markers Market Analysis, 2010-2017
Figure 6-1 Total Cardiac Markers Market Analysis, 2010-2017
CHAPTER SEVEN: CARDIAC CONTRAST AGENTS
Table 7-1 Total Cardiac Diagnostic Contrast Agent and Radiopharmaceuticals Market Analysis,2010-2017
Figure 7-1 Total Cardiac Diagnostic Contrast Agent and Radiopharmaceuticals Market Analysis,2010-2017
CHAPTER NINE: MARKET TRENDS AND SUMMARY
Table 9-1 Global Cardiac Diagnostics Market Analysis, 2010-2017
Figure 9-1 Global Cardiac Diagnostics Market Analysis: 2010-2017
Table 9-2 Global Cardiac Diagnostics by Type Revenues and Percent of Market 2012 (in millions of dollars at the manufacturers’ level)
Figure 9-2 Global Cardiac Diagnostics by Type Revenues and Percent of Market 2012
Table 9.3 Global Cardiac Diagnostic by Type Revenues and Percent of Market 2017 (in millions of dollars at the manufacturers’ level)
Figure 9-3 Global Cardiac Diagnostics by Type Revenues and Percent of Market 2016
Table 9-4 Global Cardiac Diagnostics Market Revenues by Region 2012 ($millions)
Figure 9-4 Global Cardiac Diagnostics Market Revenues by Region 2012 ($millions)
Figure 9-5 Global Cardiac Diagnostics by Region Percent 2012 (%)
Table 9-5 Global Cardiac Diagnostics Market Revenues by Region 2017 ($millions)
Figure 9-6 Global Cardiac Diagnostics Market Revenues by Region 2017 ($millions)
Figure 9-7 Global Cardiac Diagnostics by Region Percent 2017 (%)
Table 9-6 Estimated Global Cardiac Diagnostics Manufacturer Market Share 2012
Figure 9-8 Estimated Global Cardiac Diagnostics Revenues and Market Share 2012
CHAPTER TEN: INDUSTRY DEVELOPMENTS AND TECHNOLOGIES ..165
Table 10-1 Total Global Population by Selected Geographical Region, 2000 - 2050
Table 10-2 Cardiovascular Deaths by World Region 2008
Table 10-3 The U.S. Population, 1980-2020
Figure 10-1 The US Population, 1980-2020 (in millions)
Table 10-4 Percent U.S. Population Over Age 65 by Year
Figure 10-2 Estimated Population by Age Group, 2000 and 2050
Table 10-5 Average U.S. Life Expectancy in Years 1980, 2004, 2006, 2010, 2011 (years)
Figure 10-3 Average U.S. Life Expectancy in Years 1980, 2004, 2006, 2010, 2011
APPENDIX
Blood flow through coronary vessels is determined by the same physicalprinciples that govern flow to other vessels of the body, namely, driving pressureand vascular resistance to flow. Driving pressure through the coronary arteries isdetermined by aortic blood pressure and right atrial pressure.
Coronary vascular resistance has two major determinants: (1) coronaryartery diameter and (2) the degree of extra compression due to myocardialcontraction. Coronary artery diameter is continuously adjusted to maintain bloodflow at a level adequate for myocardial demands. Autoregulation is the term used todescribe the intrinsic ability of the arteries to adjust blood flow according to tissueneeds. Vasodilation occurs in response to increased tissue metabolism, whereasdecreased metabolic activity results in a decreased vessel diameter.
The mechanism of autoregulation can be explained by the metabolichypothesis, which proposes that increase metabolism results in a buildup ofvasodilatory chemicals in the vessel. Smooth muscle circling the vessel relaxes inresponse to the presence of the chemicals increasing vessel diameter. Severalvasodilation substances have been proposed, including potassium ions, hydrogenions, carbon dioxide, nitric oxide, prostaglandins, and adenosine.
The endothelialcells that line vessels are known to secrete a variety of relaxing and constrictingfactors, many of which have not yet been identified. An increase in the level ofadenosine is currently believed to be the chief vasodilatory chemicals. Low level ofoxygen in the blood also may cause vasodilation. Whatever their identity thevasodilatory substances are washed away as blood flow increases in response toincreased vessel diameter. A declining level of vasodilatory chemicals results invasoconstriction. Thus, vessel diameter is continuously adjusted according toconcentrations of vasodilatory chemicals, which are directly related to the tissuesmetabolic activity.
